Updated:
Gushengtang
Gushengtang was founded in 2019 by Tu Zhiliang, who serves as Chairman and CEO. His control is structured through Action Thrive Group Limited and Gushitang Ltd...
Gushengtang
Gushengtang was founded in 2019 by Tu Zhiliang, who serves as Chairman and CEO. His control is structured through Action Thrive Group Limited and Gushitang Ltd alongside a family trust, the TZL Family Trust, consolidating ownership around the founder's vision for an integrated TCM platform. The firm operates a growing network of clinics and hospitals while also pursuing drug development and standardized physician education, making it an unusual hybrid of healthcare operator and vertically integrated corporate investor. Gushengtang's model covers the full TCM value chain — outpatient care, inpatient services, proprietary herbal drug R&D, and talent development through formalized training programs. Its clinical network spans China's top-tier cities (Guangzhou, Beijing, Shanghai, Shenzhen) and Singapore, representing a deliberate concentration in high-density, high-income urban centers. The firm's investor base shapes its strategy: Boyu Capital committed $110 million via a convertible bond subscription in 2026 (per firm disclosures, 2026), supporting domestic clinic expansion, while August Global Partners backs Southeast Asian entry. Early backers include Starr International and Eight Roads, linking Gushengtang to long-duration insurance and growth-equity capital. Gushengtang operates clinics and hospitals in at least five major cities, with its headquarters on Qingsha Road in Guangzhou's Nansha District. While precise team size is undisclosed, the network footprint implies substantial clinical and administrative staffing. The firm coordinates its philanthropic activity through the Gushengtang People-Charity Fund, a vehicle that signals structured community engagement separate from commercial operations. In 2026, the Boyu Capital convertible bond became the most significant known operational milestone, marking a transition from early-stage backing to growth-focused institutional capital. Structurally, Gushengtang operates as a corporate entity rather than a traditional Single Family Office, using its balance sheet and strategic investor relationships to fund expansion. The combination of a founder control trust, a network of operating healthcare assets, and institutional co-investors gives it a posture distinct from both pure investment holding companies and physician-led clinical groups. Governance rests with Tu Zhiliang through founder shares and trust structures, with no publicly disclosed path to external professional management succession.
General information
Firm type
Corporate Investor
Year founded
2019
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Guangzhou
Corporate office
Room 005, No. 419 Qingsha Road, Dongchong Town, Nansha District, Guangzhou, China
Additional offices
Beijing, China · Shanghai, China · Shenzhen, China · Singapore
Principals
Tu Zhiliang
Founder, Chairman, and CEO
Sector focus
Frequently asked questions
Who controls investment decisions at Gushengtang?
Founder Tu Zhiliang, as Chairman and CEO, directs capital allocation. His control is reinforced through his holdings in Action Thrive Group Limited and Gushitang Ltd and the TZL Family Trust, which centralize ownership around the founding family. Strategic investment partners like Boyu Capital and August Global Partners participate alongside the firm but do not publicly claim decision-making authority.
How does Gushengtang source new clinic and hospital opportunities?
Gushengtang expands its TCM clinical network through direct development in major Chinese cities and targeted international entry, as seen in Singapore. While no proprietary deal-flow channel is publicly disclosed, its expansion pattern suggests a relationship-driven model tied to local regulatory approvals, physician partnerships, and its institutional investor networks.
Does Gushengtang manage outside capital or operate as a single-family office?
Gushengtang is a corporate investor, not a single-family office. It uses its own balance sheet, founder equity, and strategic institutional capital (via structures like Boyu Capital's convertible bond) to fund clinic and hospital growth. There is no evidence that it manages third-party discretionary capital in a fund-of-funds or multi-family-office structure.
Where does the underlying wealth come from?
The precise wealth origin is not publicly detailed, but it is tied to founder Tu Zhiliang and his initial capitalization of the TCM clinic and hospital network beginning in 2019. Institutional backing from Starr International and Eight Roads followed, implying pre-2019 operational or investment experience that enabled the launch of a multi-city healthcare platform.
How is Gushengtang related to the TZL Family Trust?
The TZL Family Trust, established by Tu Zhiliang, functions as a succession and asset-holding vehicle for the founder's stake in Gushengtang. It sits alongside Action Thrive Group Limited and Gushitang Ltd in the ownership structure, centralizing family control and likely serving as the long-term governance backbone as the healthcare network scales.
Does Gushengtang maintain philanthropic structures?
Yes, the Gushengtang People-Charity Fund is a named philanthropic vehicle operated by the firm. Its activities are not extensively detailed in public records, but its existence indicates a formalized community or health-related giving program separate from the core clinical business.
What is Gushengtang's known posture on co-investments alongside external partners?
Gushengtang co-invests with strategic partners on direct initiatives, as demonstrated by August Global Partners' involvement in Southeast Asian expansion and Boyu Capital's structured growth capital. The firm appears to use co-investment selectively for geographic or capital-intensive projects, rather than operating a recurring club-deal program for external allocators.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: